# Successful Use of Extracorporeal LVAD for Cardiogenic Shock with Aortic Valve Regurgitation as Bridge to Surgery

**Authors:** Takura Taguchi, Takuji Kawamura, Daisuke Yoshioka, Shunsuke Saito, Ai Kawamura, Yusuke Misumi, Shigeru Miyagawa

PMC · DOI: 10.70352/scrj.cr.25-0343 · Surgical Case Reports · 2025-07-26

## TL;DR

A patient with cardiogenic shock and aortic valve regurgitation was successfully treated with an extracorporeal LVAD as a bridge to surgery.

## Contribution

This case demonstrates the effectiveness of extracorporeal LVAD in managing cardiogenic shock with aortic regurgitation when conventional devices fail.

## Key findings

- Extracorporeal LVAD improved hemodynamics and organ function in a patient with cardiogenic shock and aortic valve regurgitation.
- The patient successfully underwent surgery after LVAD support, including aortic valve replacement and other procedures.
- Conventional devices like VA-ECMO and Impella may be inadequate for left ventricular unloading in aortic regurgitation cases.

## Abstract

Intra-aortic balloon pumping (IABP), Impella, and veno-arterial extracorporeal membrane oxygenation (VA-ECMO) are common percutaneous devices used to manage hemodynamic instability in patients with cardiogenic shock. These devices play a critical role in providing circulatory support. However, they may fail to achieve sufficient left ventricular unloading in patients with aortic valve regurgitation (AR), potentially complicating treatment strategies. In such challenging cases, an extracorporeal left ventricular assist device (LVAD) may serve as an effective alternative solution.

A 61-year-old man presented with heart failure and cardiogenic shock, further complicated by AR. Despite intensive inotropic therapy, his condition deteriorated, leading to significant hepatic and renal dysfunction. Echocardiography revealed left ventricular dysfunction with an ejection fraction of 23.5%, as well as moderate aortic, mitral, and tricuspid valve regurgitation. Initial management with VA-ECMO proved inadequate, necessitating the implantation of an extracorporeal LVAD. This intervention resulted in marked improvements in hemodynamics and multi-organ function. Subsequently, the patient underwent successful surgical procedures, including aortic valve replacement, mitral and tricuspid annuloplasty, and pulmonary vein isolation. He was discharged on day 51.

This case highlights the challenges in managing cardiogenic shock with AR, where conventional devices like IABP, Impella, and VA-ECMO may exacerbate the condition. The use of an extracorporeal LVAD provided effective left ventricular unloading, enabling successful preoperative optimization and surgery. This case supports the utility of LVAD as a bridge to surgery in patients with cardiogenic shock and AR, suggesting a need for further research into optimal management strategies in such complex cases.

## Linked entities

- **Diseases:** cardiogenic shock (MONDO:0800175), heart failure (MONDO:0005252)

## Full-text entities

- **Genes:** SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, LRPAP1 (LDL receptor related protein associated protein 1) [NCBI Gene 4043] {aka A2MRAP, A2RAP, HBP44, MYP23, RAP, alpha-2-MRAP}, GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}
- **Diseases:** PRESENTATION (MESH:D001946), left ventricular dysfunction (MESH:D018487), SD (MESH:D012735), atrial flutter (MESH:D001282), Mitral valve regurgitation (MESH:D008944), heart failure (MESH:D006333), pulmonary congestion (MESH:D001261), dyspnea (MESH:D004417), AR (MESH:D001022), Cardiogenic Shock (MESH:D012770), Hepatic and renal dysfunction (MESH:D008107), Shock (MESH:D012769), PAP (OMIM:102200), coagulopathy (MESH:D001778)
- **Chemicals:** dobutamine (MESH:D004280), oxygen (MESH:D010100), creatinine (MESH:D003404), ACKNOWLEDGMENTS (-), bilirubin (MESH:D001663)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12310382/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12310382/full.md

## References

6 references — full list in the complete paper: https://tomesphere.com/paper/PMC12310382/full.md

---
Source: https://tomesphere.com/paper/PMC12310382